Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 836880 + Ezabenlimab in advanced solid tumors
NCT03468426Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2018
- Primary completion
- Jul 2024
- Modality
- Bispecific Antibodies, Nanobodies (VHH)
- Countries
- 12
01
Overview
Phase 1, open-label trial of BI 836880 in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), glioblastoma (GBM) and 2 more (11 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose Limiting Toxicity at 21 days and Objective Response up to 778 days. Started Jul 2018; status: completed.
02
Drugs
BI 836880
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)glioblastoma (GBM)melanomahepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03468426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03468426.